Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-027818
Filing Date
2023-08-07
Accepted
2023-08-07 16:54:49
Documents
90
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q aqst-20230630.htm   iXBRL 10-Q 1149359
2 EX-31.1 aqst-06302023ex311.htm EX-31.1 10887
3 EX-31.2 aqst-06302023ex312.htm EX-31.2 11103
4 EX-32.1 aqst-06302023ex321.htm EX-32.1 6382
5 EX-32.2 aqst-06302023ex322.htm EX-32.2 6448
  Complete submission text file 0001628280-23-027818.txt   6886760

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aqst-20230630.xsd EX-101.SCH 62214
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT aqst-20230630_cal.xml EX-101.CAL 63808
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT aqst-20230630_def.xml EX-101.DEF 296507
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aqst-20230630_lab.xml EX-101.LAB 637093
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aqst-20230630_pre.xml EX-101.PRE 465499
84 EXTRACTED XBRL INSTANCE DOCUMENT aqst-20230630_htm.xml XML 848612
Mailing Address 30 TECHNOLOGY DRIVE WARREN NJ 07059
Business Address 30 TECHNOLOGY DRIVE WARREN NJ 07059 908-941-1900
Aquestive Therapeutics, Inc. (Filer) CIK: 0001398733 (see all company filings)

EIN.: 208623253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38599 | Film No.: 231148264
SIC: 2834 Pharmaceutical Preparations